Robert Barrow
CIK 1897557 · Chief Executive Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$48.75M
Companies
2
Total Filings
51
Lifetime Open-Market Net
-$3.54M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Executive Officer | 1,098,246 | $44.39 | $48.75M | -$1.77M | 4 | 2026-06-26 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Executive Officer | 778,477 | $15.00 | $11.68M | -$1.77M | 35 | 2025-12-29 |
Recent Filings · Page 3 of 6
51 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-25 | DFTX | Notice (144) | −15,659 | -$113.1K | EDGAR |
| 2024-06-25 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −15,659 | -$113.1K | EDGAR |
| 2024-03-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −16,519 | -$156.9K | EDGAR |
| 2024-03-25 | DFTX | Notice (144) | −16,519 | -$156.9K | EDGAR |
| 2024-02-29 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −13,237 | -$48.1K | EDGAR |
| 2023-12-26 | DFTX | Notice (144) | −13,237 | -$48.1K | EDGAR |
| 2023-09-25 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −13,499 | -$48.3K | EDGAR |
| 2023-09-25 | DFTX | Notice (144) | −8,231 | -$29.5K | EDGAR |
| 2023-06-27 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −15,502 | -$49.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.